Omar Mohamedaly, MD
Pulmonary Disease · Scottsdale, AZNPI 1154640704
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,689 of the $1,814 with a category attached, or 93.1%. Boehringer Ingelheim accounts for 93.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $1,689 and has fallen 99.2% since, to $14 in 2022. That places this record below the midpoint for pulmonary disease clinicians in AZ, where the typical reported total is $2,499.
Across 3 payments — averaging $604.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- AbbVie$111
- Chiesi USA, Inc.$14
Across 9 payments — averaging $24,546 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$221K
What the payments were for
- Speaking & faculty fees$1,68993%
- Food & beverage$1116%
- Education$141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $1,689 |
| AbbVie | 1 | $111 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,814 in reported general payments places this provider in the 40th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 88 | $2,226,080 |
| ZenpepLipase/Protease/Amylase | 23 | $167,467 |
| CaystonAztreonam Lysine | 11 | $128,629 |
| PrevymisLetermovir | 12 | $85,131 |
| NulojixBelatacept | 20 | $77,651 |
| Atovaquone | 24 | $23,015 |
| EliquisApixaban | 17 | $22,258 |
| Valganciclovir Hcl | 38 | $9,617 |
| Everolimus | 17 | $8,937 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,358 |
| Tacrolimus | 29 | $3,815 |
| Dapsone | 13 | $1,610 |
| Azithromycin | 113 | $1,197 |
| Nystatin | 17 | $743 |
| Pregabalin | 26 | $622 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Scottsdale
- Suchitra PilliScottsdale$38K
- Laszlo VaszarScottsdale$18K
- George ParidesMesa$913K
- Rajat WaliaPhoenix$748K
- Abhinav MittalTucson$570K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Richard SueGilbert$224K
- Mark GotfriedPhoenix$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.